Spero Therapeutics, Inc.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $66.8M | $48.0M | $103.8M | $53.5M | $18.3M | $9.3M | $18.1M | $4.0M |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | $38.5M | $96.8M | $51.4M | $47.6M | $64.5M | $67.0M | $65.8M | $33.9M |
| SG&A Expense | $21.2M | $23.7M | $25.6M | $36.5M | $41.7M | $21.4M | $15.6M | $12.9M |
| Operating Income | $6.3M | $-73.4M | $21.5M | $-42.2M | $-88.0M | $-79.1M | $-63.2M | $-42.8M |
| Operating Margin | 9.5% | -152.9% | 20.7% | -78.9% | -481.9% | -847.9% | -348.4% | -1,079.3% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | $8.8M | $-68.6M | $25.4M | $-46.4M | $-89.8M | $-78.3M | $-60.9M | $-41.7M |
| Income Tax Expense | $261.0K | $0 | $2.6M | $0 | $0 | $0 | $0 | $0 |
| Net Income | $8.6M | $-68.6M | $22.8M | $-46.4M | $-89.8M | $-78.3M | $-60.9M | $-41.7M |
| Net Margin | 12.8% | -142.9% | 22.0% | -86.7% | -491.9% | -839.2% | -335.6% | -1,051.4% |
| EPS (Basic) | $0.15 | $-1.27 | $0.43 | $-1.23 | $-2.91 | $-3.52 | $-3.35 | $-2.60 |
| EPS (Diluted) | $0.15 | $-1.27 | $0.43 | $-1.23 | $-2.91 | $-3.52 | $-3.35 | $-2.60 |
| Shares Outstanding (Basic) | 56.0M | 54.0M | 52.7M | 37.6M | 30.9M | 29.3M | 19.2M | 17.2M |
| Shares Outstanding (Diluted) | 59.0M | 54.0M | 53.0M | 37.6M | 30.9M | 29.3M | 19.2M | 17.2M |
| Dividends Per Share | — | — | — | — | — | — | — | — |